Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.

Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, Zaprazna K, Kasparkova M, Janovska P, Verner J, Kohoutek J, Dzimkova M, Bryja V, Jaskova Z, Brychtova Y, Paruch K, Trbusek M.

Oncotarget. 2016 Sep 20;7(38):62091-62106. doi: 10.18632/oncotarget.11388.

2.

Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.

Montano R, Chung I, Garner KM, Parry D, Eastman A.

Mol Cancer Ther. 2012 Feb;11(2):427-38. doi: 10.1158/1535-7163.MCT-11-0406. Epub 2011 Dec 27.

3.

Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.

Herůdková J, Paruch K, Khirsariya P, Souček K, Krkoška M, Vondálová Blanářová O, Sova P, Kozubík A, Hyršlová Vaculová A.

Neoplasia. 2017 Oct;19(10):830-841. doi: 10.1016/j.neo.2017.08.002. Epub 2017 Sep 6.

4.

Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.

Zhou Z, Fang Q, Li P, Ma D, Zhe N, Ren M, Chen B, He Z, Wang J, Zhong Q, Wang J.

Life Sci. 2019 Sep 1;232:116583. doi: 10.1016/j.lfs.2019.116583. Epub 2019 Jun 18.

PMID:
31226417
5.

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T.

Blood. 2016 Feb 4;127(5):582-95. doi: 10.1182/blood-2015-05-644872. Epub 2015 Nov 12.

PMID:
26563132
6.

The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.

Kaufman KL, Jenkins Y, Alomari M, Mirzaei M, Best OG, Pascovici D, Mactier S, Mulligan SP, Haynes PA, Christopherson RI.

Oncotarget. 2015 Dec 1;6(38):40981-97. doi: 10.18632/oncotarget.5715.

7.

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, Hornbaker MJ, Qi Y, Su X, Pageon LR, Quintas-Cardama A, Post SM.

Blood Cancer J. 2016 Jun 10;6:e434. doi: 10.1038/bcj.2016.41.

8.

The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.

Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP.

Leuk Lymphoma. 2012 Jul;53(7):1367-75. doi: 10.3109/10428194.2011.647310. Epub 2012 Jan 31.

PMID:
22149137
9.

Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.

Bastin-Coyette L, Cardoen S, Smal C, de Viron E, Arts A, Amsailale R, Van Den Neste E, Bontemps F.

Biochem Pharmacol. 2011 Mar 1;81(5):586-93. doi: 10.1016/j.bcp.2010.12.009. Epub 2010 Dec 17.

PMID:
21168391
10.

Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.

Samadder P, Suchánková T, Hylse O, Khirsariya P, Nikulenkov F, Drápela S, Straková N, Vaňhara P, Vašíčková K, Kolářová H, Binó L, Bittová M, Ovesná P, Kollár P, Fedr R, Ešner M, Jaroš J, Hampl A, Krejčí L, Paruch K, Souček K.

Mol Cancer Ther. 2017 Sep;16(9):1831-1842. doi: 10.1158/1535-7163.MCT-17-0018. Epub 2017 Jun 15.

11.

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, Celeghini C, Cuneo A, Zauli G, Secchiero P.

Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.

12.

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V, Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M.

Haematologica. 2019 Apr 11. pii: haematol.2018.203430. doi: 10.3324/haematol.2018.203430. [Epub ahead of print]

13.

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.

Liu Y, Kwiatkowski DJ.

Mol Cancer Ther. 2015 Jan;14(1):174-82. doi: 10.1158/1535-7163.MCT-14-0622-T. Epub 2014 Oct 27.

14.

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S.

Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30.

PMID:
19643983
15.

CHK1 as a therapeutic target to bypass chemoresistance in AML.

David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE, Delabesse E, Cazaux C, Didier C, Récher C, Manenti S, Hoffmann JS.

Sci Signal. 2016 Sep 13;9(445):ra90. doi: 10.1126/scisignal.aac9704.

PMID:
27625304
16.

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C.

Br J Haematol. 2008 May;141(4):445-53. doi: 10.1111/j.1365-2141.2008.07046.x. Epub 2008 Mar 12.

PMID:
18341636
17.

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S.

Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11.

18.

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T.

Blood. 2017 Jul 13;130(2):156-166. doi: 10.1182/blood-2016-12-758219. Epub 2017 May 11.

PMID:
28495793
19.

The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S.

Mol Cancer Ther. 2013 Jun;12(6):878-89. doi: 10.1158/1535-7163.MCT-12-0902. Epub 2013 Mar 27.

20.

Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.

Del Nagro CJ, Choi J, Xiao Y, Rangell L, Mohan S, Pandita A, Zha J, Jackson PK, O'Brien T.

Cell Cycle. 2014;13(2):303-14. doi: 10.4161/cc.27055. Epub 2013 Feb 1.

Supplemental Content

Support Center